Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 1
2015 1
2016 1
2019 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C; PIONEER 5 Investigators. Mosenzon O, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189517 Free article. Clinical Trial.
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR; Anti-IL-21–liraglutide Study Group investigators and contributors. von Herrath M, et al. Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. Epub 2021 Mar 1. Lancet Diabetes Endocrinol. 2021. PMID: 33662334 Clinical Trial.
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ. Fleseriu M, et al. Among authors: vagapova g. Lancet Diabetes Endocrinol. 2022 Feb;10(2):102-111. doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22. Lancet Diabetes Endocrinol. 2022. PMID: 34953531 Clinical Trial.
[Biochemical and immunological markers of autoimmune thyroiditis].
Biktagirova EM, Sattarova LI, Vagapova GR, Skibo YV, Chuhlovina EN, Kravtsova OA, Abramova ZI. Biktagirova EM, et al. Among authors: vagapova gr. Biomed Khim. 2016 May;62(4):458-65. doi: 10.18097/PBMC20166204458. Biomed Khim. 2016. PMID: 27563001 Russian.
Self-assembling systems based on amphiphilic alkyltriphenylphosphonium bromides: elucidation of the role of head group.
Gainanova GA, Vagapova GI, Syakaev VV, Ibragimova AR, Valeeva FG, Tudriy EV, Galkina IV, Kataeva ON, Zakharova LY, Latypov SK, Konovalov AI. Gainanova GA, et al. Among authors: vagapova gi. J Colloid Interface Sci. 2012 Feb 1;367(1):327-36. doi: 10.1016/j.jcis.2011.10.074. Epub 2011 Nov 10. J Colloid Interface Sci. 2012. PMID: 22134214 Free article.